RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oncosil Medical Stock

Oncosil Medical EBIT 2024

Oncosil Medical EBIT

-12.78 M AUD

Ticker

OSL.AX

ISIN

AU000000OSL3

WKN

A1WZU4

In 2024, Oncosil Medical's EBIT was -12.78 M AUD, a 13.38% increase from the -11.27 M AUD EBIT recorded in the previous year.

The Oncosil Medical EBIT history

YEAREBIT (undefined AUD)
2027e-
2026e-9.32
2025e11.72
2024e-12.78
2023-11.27
2022-10.57
2021-10.46
2020-4.34
2019-8.58
2018-8.5
2017-7.05
2016-4.77
2015-2.63
2014-4.44
2013-0.89
2012-0.28
2011-0.39
20100.04
2009-0.45
2008-2.95
2007-1.67
2006-0.13
2005-0.03
2004-

Oncosil Medical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Oncosil Medical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Oncosil Medical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Oncosil Medical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Oncosil Medical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Oncosil Medical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Oncosil Medical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Oncosil Medical’s growth potential.

Oncosil Medical Revenue, EBIT and net profit per share

DateOncosil Medical RevenueOncosil Medical EBITOncosil Medical Net Income
2027e60.5 M AUD0 AUD0 AUD
2026e34.6 M AUD-9.32 M AUD-45.1 M AUD
2025e14 M AUD11.72 M AUD38.22 M AUD
2024e4.87 M AUD-12.78 M AUD-41.54 M AUD
2023430,280 AUD-11.27 M AUD-11.34 M AUD
20221.07 M AUD-10.57 M AUD-10.73 M AUD
20211.38 M AUD-10.46 M AUD-10.43 M AUD
20202.87 M AUD-4.34 M AUD-4.26 M AUD
20193.83 M AUD-8.58 M AUD-8.57 M AUD
20184.59 M AUD-8.5 M AUD-8.54 M AUD
20173.76 M AUD-7.05 M AUD-7.02 M AUD
20164.1 M AUD-4.77 M AUD-4.77 M AUD
20153.03 M AUD-2.63 M AUD-2.88 M AUD
2014250,000 AUD-4.44 M AUD-4.22 M AUD
2013100,000 AUD-890,000 AUD-880,000 AUD
2012140,000 AUD-280,000 AUD-430,000 AUD
2011110,000 AUD-390,000 AUD-1.46 M AUD
20102.11 M AUD40,000 AUD-1.71 M AUD
20092.37 M AUD-450,000 AUD-440,000 AUD
20082.19 M AUD-2.95 M AUD-2.77 M AUD
20071.85 M AUD-1.67 M AUD-1.67 M AUD
20061.54 M AUD-130,000 AUD-130,000 AUD
200510,000 AUD-30,000 AUD-30,000 AUD
20040 AUD0 AUD0 AUD

Oncosil Medical stock margins

The Oncosil Medical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oncosil Medical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oncosil Medical.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Oncosil Medical's sales revenue. A higher gross margin percentage indicates that the Oncosil Medical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Oncosil Medical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Oncosil Medical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Oncosil Medical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Oncosil Medical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Oncosil Medical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Oncosil Medical Margin History

Oncosil Medical Gross marginOncosil Medical Profit marginOncosil Medical EBIT marginOncosil Medical Profit margin
2027e-269.24 %0 %0 %
2026e-269.24 %-26.92 %-130.32 %
2025e-269.24 %83.71 %273.01 %
2024e-269.24 %-262.56 %-853.4 %
2023-269.24 %-2,619.9 %-2,636.17 %
20229.41 %-984.39 %-999.21 %
202130.4 %-757.48 %-755.61 %
2020-269.24 %-151.32 %-148.57 %
2019-269.24 %-224.05 %-223.66 %
2018-269.24 %-185.01 %-185.95 %
2017-269.24 %-187.82 %-186.81 %
2016-269.24 %-116.25 %-116.22 %
2015-269.24 %-86.87 %-95.08 %
2014-269.24 %-1,776 %-1,688 %
2013-269.24 %-890 %-880 %
2012-269.24 %-200 %-307.14 %
2011-269.24 %-354.55 %-1,327.27 %
201034.12 %1.9 %-81.04 %
200938.4 %-18.99 %-18.57 %
200850.23 %-134.7 %-126.48 %
200748.11 %-90.27 %-90.27 %
200662.34 %-8.44 %-8.44 %
2005-269.24 %-300 %-300 %
2004-269.24 %0 %0 %

Oncosil Medical Aktienanalyse

What does Oncosil Medical do?

Oncosil Medical Ltd is an Australian company specializing in the development and distribution of innovative medical products for the treatment of cancer. The company was founded in 2005 and is based in Sydney. The business model of Oncosil Medical is based on research, development, and marketing of products specifically tailored to the needs of cancer patients. The company focuses on developing medical products that aim to improve the effectiveness of radiation therapy and chemotherapy. The core product of Oncosil Medical is the Oncosil implant. It is a small, implantable catheter containing tiny radioactive silicon particles. The implant is directly inserted into the tumor and releases controlled radiation to specifically destroy the tumor. The Oncosil implant is a promising and innovative new treatment option for many cancer patients. It is particularly suitable for patients with locally advanced pancreatic cancer, which is especially difficult to treat. Studies have shown that the Oncosil implant can significantly improve patients' survival rate. Oncosil Medical also provides other products, such as the Microsil transponder. The Microsil transponder is a small implant used in radiation therapy to make the irradiation of the tumor more effective. The transponder is directly inserted into the tumor, allowing medical professionals to precisely target the radiation to the tumor. In addition to developing and marketing innovative medical products, Oncosil Medical also has a research and development department. The company is constantly searching for new cancer treatment methods and works closely with scientists and researchers to develop new technologies. Oncosil Medical operates in several areas. In addition to developing and marketing medical products, the company also offers a training and education program for doctors and medical personnel. The program ensures that all users of Oncosil Medical's products have the necessary skills and knowledge to use the products safely and effectively. The company also has its own regulatory affairs department, which deals with the application for approvals for new products and procedures. This department works closely with authorities and regulatory agencies to ensure that all products from Oncosil Medical comply with applicable regulations and standards. Overall, Oncosil Medical is an innovative and emerging company specializing in the development and marketing of medical products for cancer treatment. With its highly skilled team of scientists, doctors, and qualified professionals, the company stays up to date with the latest research and technology to ensure that its products are always state-of-the-art and provide customers with the best possible treatment option. Oncosil Medical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Oncosil Medical's EBIT

Oncosil Medical's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Oncosil Medical's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Oncosil Medical's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Oncosil Medical’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Oncosil Medical stock

How much did Oncosil Medical achieve in EBIT for the current year?

In the current year, Oncosil Medical has achieved an EBIT of -12.78 M AUD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Oncosil Medical.

How has the EBIT of Oncosil Medical developed in recent years?

The EBIT of Oncosil Medical has increased by 13.383% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Oncosil Medical?

The EBIT of Oncosil Medical is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Oncosil Medical pay?

Over the past 12 months, Oncosil Medical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncosil Medical is expected to pay a dividend of 0 AUD.

What is the dividend yield of Oncosil Medical?

The current dividend yield of Oncosil Medical is .

When does Oncosil Medical pay dividends?

Oncosil Medical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncosil Medical?

Oncosil Medical paid dividends every year for the past 0 years.

What is the dividend of Oncosil Medical?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncosil Medical located?

Oncosil Medical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncosil Medical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncosil Medical from 9/13/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Oncosil Medical pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Oncosil Medical in the year 2023?

In the year 2023, Oncosil Medical distributed 0 AUD as dividends.

In which currency does Oncosil Medical pay out the dividend?

The dividends of Oncosil Medical are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oncosil Medical

Our stock analysis for Oncosil Medical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncosil Medical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.